论文部分内容阅读
[目的]探讨多西他赛在晚期食管鳞癌患者二线治疗中的疗效及不良反应。[方法]回顾性分析85例晚期食管鳞癌患者,所有患者均为一线治疗进展后采用二线多西他赛治疗。Kaplan-Meier法进行生存分析。Cox法对影响患者预后的因素进行多因素分析。[结果]患者中位无进展生存期为3.5个月,中位生存期为5.5个月。一线化疗达到部分缓解的患者多西他赛治疗疗效优于一线治疗后稳定及进展的患者(4.0个月vs 3.2个月,P=0.015)。多数患者能够耐受不良反应,发生Ⅲ~Ⅳ度不良反应的患者比例为25.8%。[结论]多西他赛在二线食管鳞癌患者中有一定的疗效。一线治疗中疗效好的患者采用多西他赛二线治疗疗效较好。
[Objective] To investigate the efficacy and adverse reactions of docetaxel in second-line treatment of advanced esophageal squamous cell carcinoma. [Methods] A retrospective analysis of 85 patients with advanced esophageal squamous cell carcinoma, all patients were treated with second-line docetaxel after the first-line treatment. Kaplan-Meier method for survival analysis. Cox method to predict the prognosis of patients with multivariate analysis of factors. [Results] The median progression-free survival was 3.5 months and the median survival was 5.5 months. Docetaxel was superior to first-line stable and advanced patients in the first-line chemotherapy (4.0 months versus 3.2 months, P = 0.015) in patients who achieved partial remission. Most patients were able to tolerate adverse reactions, the proportion of patients with grade Ⅲ ~ Ⅳ adverse reactions was 25.8%. [Conclusion] Docetaxel has a certain curative effect in patients with second-line esophageal squamous cell carcinoma. First-line treatment in patients with good effect of docetaxel second-line treatment is better.